🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors

RecruitingNAAges 18 Years - anyAllInstitute for Clinical and Experimental Medicine
NCT07536087 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The primary aim of this study is to evaluate the technical feasibility and effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) in the treatment of pancreatic cystic neoplasms (PCNs) and pancreatic neuroendocrine tumors (pNETs) in patients who are not suitable candidates for surgical treatment or who refuse surgery. EUS-RFA, as a minimally invasive therapeutic option, may potentially reduce the need for intensive imaging surveillance, prevent further progression of these lesions, and serve as a bridging therapy in selected patients for whom surgical intervention may be considered in the future. At the same time, EUS-RFA could contribute to reducing overtreatment, thereby lowering the risk of complications associated with surgical procedures and leading to an overall reduction in healthcare costs. The secondary objectives of the study are to evaluate the safet

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Consensual indication to EUS-guided RFA treatment made in a multidisciplinary team * Capability of giving informed consent PCN Inoperability or refusal of surgery * Branch duct IPMN (BD-IPMN) with worrisome features: * Jaundice * High grade dysplasia or cancer * Solid mass/nodule \> 5mm * Main pancreatic duct dilation \> 10mm Or at least one (patients without comorbidities) or at least two (patient with comorbidities) of the following risk features: * CA 19-9\> 37 U/ml * Increase in size \> 5mm/year * Dilation of the main pancreatic duct between 5-10mm * Size ≥ 40mm * Symptoms (new onset of diabetes, acute pancreatitis) * Nodule \< 5mm Pancreatic NET * Size \< 2 cm * Histological proof in non-functional lesions/histological proof or clinical proof in functional lesions * 68Ga-DOTATATE PET/CT positive for a pancreatic lesion and negative for lymph nodes, liver, and other distant metastases * G1 or G2 (\<5 %) histology Exclusion Criteria: * Known bleeding disorder that cannot be sufficiently corrected with medication * Use of anticoagulants that cannot be discontinued * Physical and/or psychological inability to understand the aims of the research and to adequately cooperate * Pregnancy * Inability to sign the informed consent
💊

What it tests

  • Endoscopic ultrasound-guided radiofrequency ablation for pancreatic cystic lesions
  • Endoscopic ultrasound-guided radiofrequency ablation of pancreatic solid lesions
📍

Where

1 site
Institute for Clinical and Experimental Medicine, Department of Gastroenterology and Hepatology
Prague, Czechia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy